Drugstore chain Rite Aid reported solid third-quarter results on Thursday after a strong start to its flu-immunization program and the completed addition of Wellness stores. However, shares of Rite Aid are down after the company lowered its profit forecast and revenue outlook for the year. While third-quarter revenue beat analysts' expectations and earnings per share came in line with estimates, investors are focusing on Rite Aid's lowered 2014 guidance that now comes in below analysts' estimates.
More from Video
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.